Expression of the breast cancer resistance protein in breast cancer

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1068-1074

  Faneyte, Ian F ^a,b   Kristel, Petra M P ^a   Maliepaard, Marc ^a   Scheffer, George L ^c   Scheper, Rik J ^c   Schellens, Jan H M ^a   Van De Vijver, Marc J ^b  

^a Division of Experimental Therapy   (Netherlands)

^b Departments of Pathology   (Netherlands)

^c Division of Medical Oncology   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BREAST CANCER RESISTANCE PROTEIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MESSENGER RNA; ONCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE;

ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, NORTHERN; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0036554732     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kroger, N., Achterrath, W., Hegewisch-Becker, S., Mross, K., and Zander, A. R. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat. Rev., 25: 279-291, 1999.
2. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells [published erratum appears in Proc. Natl. Acad. Sci. USA, 96: 2569, 1999]. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.
3. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V., and Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339, 1998.
4. Lee, J. S., Scala, S., Matsumoto, Y., Dickstein, B., Robey, R., Zhan, Z., Altenberg, G., and Bates, S. E. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J. Cell Biochem., 65: 513-526, 1997.
5. Chen, Y. N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J. L., and Fojo, A. T. Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem., 265: 10073-10080, 1990.
6. Ma, J., Maliepaard, M., Nooter, K., Loos, W. J., Kolker, H. J., Verweij, J., Stoter, G., and Schellens, J. H. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br. J. Cancer, 77: 1645-1652, 1998.
7. Ross, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P., and Doyle, L. A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst., 91: 429-433, 1999.
8. Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D. D., Miyake, K., Resau, J. H., and Bates, S. E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci., 113(Pt. 11): 2011-2021, 2000.
9. Ross, D. D. Novel mechanisms of drug resistance in leukemia. Leukemia (Baltimore), 14: 467-473, 2000.
10. Ross, D. D., Karp, J. E., Chen, T. T., and Doyle, L. A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood, 96: 365-368, 2000.
11. Scheffer, G. L., Maliepaard, M., Pijnenborg, A. C., van Gastelen, M. A., de Jong, M. C., Schroeijers, A. B., van der Kolk, D. M., Allen, J. D., Ross, D. D., van der Valk, P., Dalton, W. S., Schellens, J. H., and Scheper, R. J. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res., 60: 2589-2593, 2000.
12. Allen, J. D., Brinkhuis, R. F., Wijnholds, J., and Schinkel, A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res., 59: 4237-4241, 1999.
13. Jonker, J. W., Smit, J. W., Brinkhuis, R. F., Maliepaard, M., Beijnen, J. H., Schellens, J. H., and Schinkel, A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 92: 1651-1656, 2000.
14. Rabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W., and Greenberger, L. M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res., 60: 47-50, 2000.
15. Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp-Helmers, M. C., Floot, B. G., and Schellens, J. H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res., 59: 4559-4563, 1999.
16. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410, 1991.
17. Rodenhuis, S., Richel, D. J., van Der, W. E., Schornagel, J. H., Baars, J. W., Koning, C. C., Peterse, J. L., Borger, J. H., Nooijen, W. J., Bakx, R., Dalesio, O., and Rutgers, E. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet, 352: 515-521, 1998.
18. Hayward, J. L., Carbone, P. P., Heuson, J. C., Kumaoka, S., Segaloff, A., and Rubens, R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer. Geneva, Switzerland. Cancer (Phila.), 39: 1289-1294, 1977.
19. Grandchamp, B., De Verneuil, H., Beaumont, C., Chretien, S., Walter, O., and Nordmann, Y. Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene. Eur. J. Biochem., 162: 105-110, 1987.
20. de Vree, J. M., Jacquemin, E., Sturm, E., Cresteil, D., Bosma, P. J., Aten, J., Deleuze, J. F., Desrochers, M., Burdelski, M., Bernard, O., Oude Elferink, R. P., and Hadchouel, M. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl. Acad. Sci. USA, 95: 282-287, 1998.
21. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., van De Vijver, M. J., Scheper, R. J., and Schellens, J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 61: 3458-3464, 2001.
22. Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Perez, W. Y., Robey, R. W., van De, L. A., Litman, T., Dean, M., and Bates, S. E. Acquired mutations in the mxr/bcrp/abcp gene alter substrate specificity in mxr/bcrp/abcp-overexpressing cells. Cancer Res., 61: 6635-6639, 2001.